



Date: 29/10/2020.

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".

Sub: Outcome of Board Meeting held on 29th October, 2020 & Submission of financial result.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 29th October, 2020 has considered and approved the following:

- Unaudited Standalone Financial result for the Quarter/Half year ended on 30th September, 2020 along Limited Review Report.

We wish to inform you that Board Meeting commenced today at 02.30 p.m. and concluded at 05.10 p.m.

We are enclosing herewith the copy of approved financial result.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited

Mr. Aakash Keshari
Company Secretary

BAJAJ HEALTHCARE LTD

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.

• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

**PARESH
RAKESH**


ASSOCIATES
Chartered Accountants

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Bajaj Healthcare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Bajaj Healthcare Limited (the "Company") for the quarter ended September 30, 2020 and year to date from April 1, 2020 to September 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Paresh Rakesh & Associates
Chartered Accountants
FRN: 119728W


Rakesh Chaturvedi
M. no: 102075
UDIN: 20102075AAAAIQ3478



Date: October 29, 2020
Place: Thane

BAJAJ HEALTHCARE LIMITED

(CTN No. : L99999MH1993PLC072892)

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON 30TH SEPTEMBER, 2020

(Rs. In Lakhs Except for Earnings Per Share)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30.09.2020	30.06.2020	30.09.2019	30.09.2020	30.09.2019	31.03.2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from operations	20,663.47	13,983.32	10,054.58	34,646.79	19,223.96	41,000.84
II. Other Income	209.49	90.17	11.68	299.67	31.91	317.91
III. Total Revenue (I+II)	20,872.96	14,073.49	10,066.26	34,946.45	19,255.87	41,318.74
IV. Expenses						
(a) Cost of materials consumed (Including Other Direct Expenses)	15,423.60	10,388.39	8,382.96	25,811.99	15,390.67	32,027.10
(b) Changes in Inventories of Finished Good	191.66	-375.67	-311.49	-184.02	-26.60	-508.76
(c) Employee benefits expense	980.37	798.73	773.57	1,778.10	1,408.57	2,817.83
(d) Finance Costs	217.18	204.81	157.43	422.00	340.10	644.93
(d) Depreciation and amortisation expense	397.54	376.47	295.22	774.01	589.38	1,212.33
(e) Other expenses	836.97	637.30	314.94	1,474.27	638.55	1,519.28
Total Expenses	18,047.32	12,030.04	9,612.64	30,077.35	18,340.67	37,712.73
V. Profit before Exceptional Items	2,825.64	2,043.46	453.62	4,869.10	915.21	3,606.02
VI. Exceptional items	-	-	-	-	-	-
VII. Profit before Extra Ordinary Items	2,825.64	2,043.46	453.62	4,869.10	915.21	3,606.02
VIII. Extra Ordinary items	-	-	-	-	-	-
VII. Profit Before Tax	2,825.64	2,043.46	453.62	4,869.10	915.21	3,606.02
VIII. Tax Expense						
(a) Current tax	826.60	573.40	110.00	1,400.00	250.00	910.00
(b) Deferred Tax	-12.63	-59.10	-0.65	-71.73	-3.02	148.91
(c) Earlier Years	-	-	20.52	-	20.52	23.44
Total Tax Expenses	813.97	514.30	129.87	1,328.27	267.49	1,082.35
IX. Profit (Loss) for the Period	2,011.67	1,529.16	323.75	3,540.83	647.71	2,523.67
X. Other comprehensive Income						
(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-25.51
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
(iv) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the Period	2,011.67	1,529.16	323.75	3,540.83	647.71	2,498.16
XI. Paid-up Equity Share Capital (Face Value Rs. 10/-)	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92	1,379.92
XII. Other Equity excluding Revaluation Reserve	-	-	-	-	-	16,405.88
XIII. EPS (Not Annualised)						
(a) Basic (in Rs.)	14.58	11.08	2.35	25.66	4.69	18.29
(b) Diluted (in Rs.)	14.58	11.08	2.35	25.66	4.69	18.29

Note :

a) The above Financial Results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on October 29, 2020.

b) As the Company was listed in SME segment of BSE Ltd as on 31st March 2019 and migrated to Main Board on 29th May 2019, Ind-AS is applicable from 1st April, 2020. Hence, the company has adopted Indian Accounting Standard ("Ind AS") as notified under Section 133 of the Companies Act, 2013 ("the Act")

c) The financial results for the Quarter and Half Year ended 30th September 2020 have been subjected to limited review by the statutory auditors of the Company. The restated comparative figures under Ind-AS prepared by the Management are after exercising necessary due diligence to ensure financial results reflects true and fair view of Company's affairs in Indian Accounting Standard ("Ind AS") for Quarter and Half Year ended 30th September 2019 and Year End figures for 31st March 2020 and are not subject to Review of the Statutory Auditors. The financial results for such period prepared under IGAAP framework were reviewed by Statutory Auditors.



d) Reconciliation of Net profit and Reserves as reported under generally accepted accounting principles (GAAP) and as per IND AS is given below:

(Rs. in Lakhs)


Particulars (As applicable)	Profit Reconciliation			Reserves
	Quarter ended Sept 30, 2019	Half Year ended Sept 30, 2019	Year Ended March 31, 2020	Reconciliation Year Ended March 31, 2020
Net profit after tax/ Reserve reported under previous GAAP	327.74	651.92	2240.05	13780.70
Adjustments increasing/(decreasing) net profit/ Reserve as reported in the previous GAAP	-5.30	-5.69	360.89	-139.96
Adjustments in Deferred Tax	1.40	1.48	-87.20	38.85
Fair Value/ Revalued figure considered as Deemed Cost for Land under Property Plant and Equipment as on 01st April 2019	-	-	-	2751.73
Net Profit after tax/ Reserve reported under Ind AS	323.75	647.71	2523.67	16431.59
Other Comprehensive Income / Loss (Net of Tax)	-	-	-25.51	-25.51
Total Comprehensive Income (after tax)/ Reserves as reported under Ind AS	323.75	647.71	2498.16	16405.98

e) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A.

f) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification.

By Order of the Board
For Bajaj Healthcare Limited

Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director



Date: 29th October 2020
Place: Thane

BAJAJ HEALTHCARE LIMITED


(CIN No. : L99999MH1993PLC072892)

STATEMENT OF ASSETS & LIABILITIES AS AT 30th SEPTEMBER 2020

(Rs in Lakhs)

Particulars		As at 30.09.2020 (Unaudited)	As at 31.03.2020 (Audited)
A	ASSETS		
	Non-current assets		
	(a) Property Plant & Equipment	17,859.98	16,224.27
	(b) Capital work-in-progress	2,483.80	544.60
	(c) Long Term Investments	500.31	500.31
	Current assets		
	(a) Inventories	7,248.97	3,927.51
	Financial Assets		
	(a) Trade receivables	11,006.10	9,847.77
	(b) Cash and cash equivalents	554.74	415.85
	(c) Other Bank Balances	192.46	184.10
	(d) Other Financial assets	10.00	10.00
	Other Current assets	2,910.98	2,640.46
	TOTAL ASSETS	42,767.33	34,294.86
B	EQUITY AND LIABILITIES		
	Equity		
	(a) Share Capital	1,379.92	1,379.92
	(b) Other Equity	19,946.71	16,405.88
	Sub - Total - Equity	21,326.63	17,785.80
	Liabilities		
	Non-Current Liabilities		
	Financial Liabilities		
	(a) Borrowings	3,784.55	2,357.82
	Deffered Tax Liabilities	110.03	181.76
	Long-term Provisions	268.16	208.91
	Current Liabilities		
	Financial Liabilities		
	(a) Trade payables	5,134.29	4,770.73
	(b) Borrowings	7,319.09	5,843.25
	(c) Other Financial Liabilities	4,159.38	2,993.70
	(d) Current Tax Liabilities	512.45	44.00
	(e) Provisions	9.87	6.93
	Other Current Liabilities	142.87	101.96
	TOTAL - EQUITY AND LIABILITIES	42,767.33	34,294.86

By Order of the Board
For Bajaj Healthcare Limited



Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

Date: 29th October 2020
Place: Thane

BAJAJ HEALTHCARE LTD.
CASH FLOW STATEMENT FOR THE PERIOD ENDED 30TH SEPTEMBER 2020
(CIN No. : L99999MH1993PLC072892)

(Rs. In Lakhs)

Sr No	Particulars	30th Sept, 2020		30th Sept, 2019	
		(Unaudited)		(Unaudited)	
		Amt in Rs.	Amt in Rs.	Amt in Rs.	Amt in Rs.
A	CASH FLOW FROM OPERATING ACTIVITIES				
	Net Profit Before Tax		4,869.10		915.21
	Adjustments for:				
	Depreciation	774.01		589.38	
	(Profit)/loss on sale of Assets	(0.48)		-	
	Interest & Finance Charges	422.00		340.10	
	Interest on FD	(2.72)		(7.30)	
	Provision for Employee Benefits & Leave Enchashment	66.37		19.64	
	ECL Provision	(74.95)		5.69	
	Dividend Income	-	1,184.22	(0.04)	947.45
	Operating Profit before Working Capital Changes		6,053.32		1,862.66
	Adjustments for:				
	(increase)/Decrease in Other current assets	(287.86)		(109.49)	
	(increase)/Decrease in Sundry Debtors	(1,083.38)		(656.23)	
	(increase)/Decrease in Inventories	(3,321.46)		(48.53)	
	Increase / (Decrease) in non current and current liabilities	1,570.15		850.91	
			(3,122.55)		36.65
	Cash generated from operations		2,930.77		1,899.31
	Income Tax Paid		(922.56)		(393.69)
	Net Cash flow from Operating activities		2,008.21		1,505.62
B.	CASH FLOW FROM INVESTING ACTIVITIES				
	Purchase of Fixed Assets	(2,412.11)		(400.60)	
	Increase/(Decrease) in Capital Wip	(1,939.20)		(626.64)	
	Sale Of Fixed Assets	2.87		-	
	Interest on FD	2.72		7.30	
	Payment to Gratuity Fund	(4.17)		(15.00)	
	Investment in Preference Shares			0.04	
	Dividend Income	-			
	Net Cash used in Investing activities		(4,349.89)		(1,034.89)
C	CASH FLOW FROM FINANCING ACTIVITIES				
	Proceeds From Long Term Borrowing	1,487.17		296.43	
	Increase of Investment in Preference Shares	-		(500.00)	
	Repayment Of Unsecured Long Term Borrowing	(60.43)		(20.97)	
	Increase / (Decrease) Of Short Term Borrowing From Bank	1,483.09		130.69	
	Increase / (Decrease) Of Borrowing From Director & Inter corpates	(7.25)		(133.86)	
	Interest paid	(422.00)		(340.10)	
	Net Cash used in financing activities		2,480.58		(567.81)
	Net increase in Cash & Cash Equivalents (A+B+C)		138.89		(97.08)
	Cash and Cash equivalents as at 01.04.2020		415.85		786.15
	Cash and Cash equivalents as at 30.09.2020		554.74		689.07

For and on behalf of the Board
For BAJAJ HEALTHCARE LIMITED



Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director

Place: Thane
Date: 29th October 2020

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR QUARTER ENDED ON 30th Sept, 2020


Annexure : A

(Rs. In Lakhs)

Sr No	Particulars	Quarter Ended			Six Months Ended		Year Ended
		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
A	Segment Revenue (Excluding Intersegment Revenue)						
	Bulk Drugs	17442.86	12568.26	9280.35	30011.13	17955.22	38607.49
	Formulations	3220.60	1415.06	774.22	4635.66	1268.73	2464.31
	Total	20,663.47	13,983.32	10,054.58	34,646.79	19,223.96	41,071.80
	InterSegment Revenue						
	Bulk Drugs	1043.69	783.46	424.70	1,827.15	988.04	2,108.98
	Formulations	29.66	3.54	10.80	33.20	41.86	86.18
	Total	1,073.34	787.01	435.49	1,860.35	1,029.89	2,195.15
	Gross Segment Revenue (Including Intersegment Revenue)						
	Bulk Drugs	18486.55	13351.73	9705.05	31838.28	18943.26	40716.46
Formulations	3250.26	1418.60	785.02	4668.86	1310.59	2550.49	
Total	21,736.81	14,770.33	10,490.07	36,507.14	20,253.85	43,266.95	
B	II. Segment Results						
	Profit / (Loss) Before Tax & Finance Cost						
	Bulk Drugs	3272.53	2,746.60	902.38	6,019.13	1,993.04	6,330.53
	Formulations	694.14	127.05	-2.73	821.19	-104.88	-224.92
	Total	3,966.67	2,873.65	899.65	6,840.32	1,888.16	6,105.61
Less : Interest	217.18	204.81	157.43	422.00	340.10	644.93	
Other Unallocable Expenditure (Net)	923.85	625.38	288.61	1,549.22	632.86	1,854.66	
Total Profit Before Tax	2,825.64	2,043.46	453.62	4,869.10	915.21	3,606.02	
C	I. Segment Assets						
	Bulk Drugs	39,224.93	37,912.63	27,732.39	39,224.93	27,732.39	31,563.91
	Formulations	3,042.09	2,547.92	2,050.53	3,042.09	2,050.53	2,230.65
	Others	500.31	500.31	500.31	500.31	500.31	500.31
	Total	42,767.33	40,960.86	30,283.22	42,767.33	30,283.22	34,294.86
	II. Segment Liabilities						
	Bulk Drugs	19,438.32	20,096.23	13,467.62	19,438.32	13,467.62	15,489.68
	Formulations	1,101.86	591.27	453.74	1,101.86	453.74	584.70
	Others	900.51	958.62	426.51	900.51	426.51	434.67
	Total	21,440.69	21,646.12	14,347.87	21,440.69	14,347.87	16,509.06
Total Capital Employed	21,326.63	19,314.74	15,935.35	21,326.63	15,935.35	17,785.80	
Total (II+III)	42,767.33	40,960.86	30,283.22	42,767.33	30,283.22	34,294.86	

By Order of the Board
For Bajaj Healthcare Limited

Place : Thane
Date: 29th October 2020



Mr. Sajankumar R Bajaj
D.No.: 00225950
Chairman and Managing Director